Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

Texas MPN Workshop 2022 | Ruxolitinib in 2022: how this agent has transformed the MF treatment landscape

Aaron Gerds • 24 Aug 2022

Texas MPN Workshop 2022

Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

COMFORT-I COMFORT-II

In this video, Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the role of ruxolitinib in the treatment of myeloproliferative neoplasms (MPNs), drawing focus on how this agent has transformed the treatment landscape of myelofibrosis (MF). Dr Gerds first provides some background information on the development and approval of ruxolitinib, and then goes on to explain how this agent has greatly improved patient outcomes over the years. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie

Real-world use of fedratinib in patients with MF who have failed on ruxolitinib

Aaron Gerds • 6 Dec 2023

Treating elderly, non-transplant eligible patients with MF

Aaron Gerds • 6 Dec 2023

The MOST study: differences in disease progression amongst patients with low-risk MF

Aaron Gerds • 6 Dec 2023

XPORT-MF-044 trial: evaluating selinexor in JAK inhibitor-naïve MF and moderate thrombocytopenia

Aaron Gerds • 6 Dec 2023

Related Videos

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023